Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

are to be treated with percutaneous coronary intervention, NSTEMI or unstable angina (NICE's technology appraisal guidance on ticagrelor for the treatment of acute coronary syndromes). 2.6 Since the publication of NICE's technology appraisal guidance 182 on prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention in October 2009, generic formulations of clopidogrel have become available and NICE has published its appraisal of ticagrelor (NICE's technology appraisal guidance on ticagrelor for the treatment of acute coronary syndromes). 3 The technology 3.1 Prasugrel (Efient, Eli Lilly and Company/Daiichi-Sankyo) is an oral inhibitor of platelet activation and aggregation. It works by the irreversible binding of its active metabolite to the P2Y12 class of adenosine diphosphate receptors on platelets. It has a marketing authorisation when co-administered with aspirin for the prevention of atherothrombotic events in adults with acute coronary syndrome (that is, unstable angina or non-ST-segment-elevation myocardial infarction [NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention. 3.2 The summary of product characteristics for prasugrel states that it should be started with a single 60 mg loading dose and then continued at 10 mg once a day. People taking prasugrel should also take 75 mg to 325
